R&D Supply Sample Clauses

R&D Supply. BD shall have the right to order, and SDIX shall be obligated to Manufacture and deliver, the quantities of Supplied Product listed on Schedule 3.2.1 [***] (the “R&D Supply”).
Sample 1
AutoNDA by SimpleDocs
R&D Supply. No later then three (3) months after the Execution Date, Par shall issue (i) a binding purchase order for [***] kg of API which shall designate the Delivery Date for [***] kg as any day prior to December 1, 2005 and [***] kg as any day prior to March 1, 2006; (ii) a binding purchase order for no less than [***] kg which shall designate the Delivery Date as any day prior to May 31, 2006; and (iii) a binding purchase order for no less than [***] kg of API which shall designate the Delivery Date for [***] kg as any day prior to July 1, 2006, and the Delivery Date for [***] as any day prior to Aug 1, 2006.
Sample 1
R&D Supply. The Delivered Price per kg for all research and development amounts of API shall be (i) [***] dollars ($[***]) for the first [***] kg, to be delivered before March 1, 2006; (ii) [***]dollars ($[***]) for the remaining [***] kg and [***] kg. The above notwithstanding, in consideration for Biocon’s timely development of the API, Par shall purchase the API at (i) [***]dollars per kg ($[***]/kg) for the initial [***] kg if Biocon delivers [***] kg prior to November 1, 2005 and [***] kg prior to January 1, 2006 and (ii) [***] dollars per kg ($[***]/kg) for the for the [***] kg if Biocon delivers all [***] kg before March 31, 2006 and the [***] kg if all [***] kg is delivered before July 1, 2006.
Sample 1
R&D Supply. Optionee will sell Licensed Products to Caltech for educational and other noncommercial purposes on a most favored customer basis. Patent Prosecution: Caltech will be responsible, in accordance with its customary patent prosecution practices, for preparing, filing, prosecuting and maintaining patent applications and patents within the Exclusively Licensed Patent Rights. Optionee will pay the reasonable patent costs and fees incurred in connection with such activities (except as specified in the next paragraph). Optionee may recommend patent counsel, and will have right of review and comment. Optionee may prosecute if Caltech declines. One hundred percent (100%) of the amounts expended by Optionee in connection with foreign patent costs shall be creditable against the Annual License Fee due Caltech. All patents and patent applications in which Optionee has paid the foregoing patent costs and fees will become a part of the Exclusively Licensed Patent Rights. Alchemy .Excl. Opt. 5/23/2006 Optionee may elect not to pay the foregoing patent costs and fees with respect to a particular patent application or patent. In the event that Optionee elects not to pay any of the foregoing patent costs and fees with respect to a particular application or patent, Caltech may, at its option, continue such prosecution or maintenance. At the sole discretion of Caltech, Optionee and Caltech may enter into negotiations for a separate agreement under which Optionee would have a nonexclusive license under any patent resulting from such prosecution or maintenance paid by Caltech.
Sample 1

Related to R&D Supply

  • Manufacturing and Supply Genentech shall be responsible for manufacturing and supplying Licensed Products for clinical use and commercial sale in the Genentech Field.

  • Product Supply 5.2.1 HEMISPHERX undertakes and agrees to supply to IMPATIENTS on an exclusive basis, IMPATIENTS’ requirements of Product ordered in accordance with the terms of this Agreement, for distribution and sale in the Territory, limited to EAP use of Product in accordance with Early Access Approvals.

  • Clinical Supply Takeda will provide to Licensee[***] the amount of TAK-385 Licensed Compound or TAK-385 Licensed Products needed by Licensee to complete all Clinical Trials contemplated by the TAK-385 Development Plan (estimated by Licensee as of the Effective Date to be [***]), solely to the extent that Takeda can supply such TAK-385 [***] = Portions of this exhibit have been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment requested under 17 C.F.R. Sections 200.80(b)(4) and 230.406. Licensed Compound or TAK-385 Licensed Products (a) from its supply of TAK-385 Licensed Compound or TAK-385 Licensed Products in existence as of the Effective Date and which supply can be used for its intended purposes without further re-processing (the “Initial Clinical Supply”) and (b) after retaining the amount needed by Takeda for Clinical Trials in the Takeda Territory. Takeda will also provide to Licensee, at [***] any additional supplies of TAK-385 Licensed Compound or TAK-385 Licensed Products in excess of the Initial Clinical Supply needed by Licensee to complete all Clinical Trials contemplated by the TAK-385 Development Plan. Within [***] days after the Effective Date, the Parties will enter into a manufacturing and supply agreement (the “Takeda Clinical Manufacturing and Supply Agreement”), which will govern the terms and conditions of the Manufacturing and supply of the TAK-385 Licensed Compound and TAK-385 Licensed Products (including the Initial Clinical Supply) by Takeda to Licensee for Development purposes, including the exact quantities and the timelines for delivery. The Parties will negotiate the terms and conditions of such Takeda Clinical Manufacturing and Supply Agreement in good faith for a period of [***] days (as may be extended upon agreement of the Parties). As part of the negotiation related to the Takeda Clinical Manufacturing and Supply Agreement, the Parties shall discuss in good faith the ability of Takeda to supply to Licensee [***]. If the Parties have not entered into a definitive agreement within such negotiation period, then the final terms and conditions of such agreement will be resolved in accordance with Section 8.2 (Arbitration for Failure to Agree).

  • Supply Agreement Buyer shall have executed and delivered the Supply Agreement to the Company.

  • Equipment and Supplies Independent Contractor, at Independent Contractor's sole expense, shall provide all equipment, tools and supplies necessary to perform the Service.

  • Manufacturing Services Jabil will manufacture the Product in accordance with the Specifications and any applicable Build Schedules. Jabil will reply to each proposed Build Schedule that is submitted in accordance with the terms of this Agreement by notifying Company of its acceptance or rejection within three (3) business days of receipt of any proposed Build Schedule. In the event of Jabil’s rejection of a proposed Build Schedule, Jabil’s notice of rejection will specify the basis for such rejection. When requested by Company, and subject to appropriate fee and cost adjustments, Jabil will provide Additional Services for existing or future Product manufactured by Jabil. Company shall be solely responsible for the sufficiency and adequacy of the Specifications [***].

  • Manufacture and Supply BMS shall Manufacture or have Manufactured the BMS Study Drug in reasonable quantities needed, and at the points in time as agreed to by the Parties, for the Combined Therapy Clinical Trial, and shall supply such BMS Study Drug as either commercially labeled or unlabeled vials to the Recipient or its designee for use solely in the Combined Therapy Clinical Trial. The Recipient will at its sole expense, package and label the BMS Study Drug for use in the Combined Therapy Clinical Trial to the extent necessary. The cost of Manufacture and supply (including shipping, taxes and duty, if applicable) of the BMS Study Drug for the Combined Therapy Clinical Trial shall be borne solely by BMS, and BMS shall bear the risk of loss for such quantities of BMS Study Drug until delivery of such quantities of BMS Study Drug to the Recipient or its designee. BMS shall also be responsible for the payment of any Third Party License Payments that may be due based on the manufacture, *CONFIDENTIAL TREATMENT REQUESTED. supply and use of the BMS Study Drug used in the Combined Therapy Clinical Trial. The BMS Study Drug shall be manufactured in accordance with Applicable Law (including GMP) and shall be of similar quality to the BMS Study Drug used by BMS for its other clinical trials of the BMS Study Drug. BMS shall deliver certificates of analysis, and any other documents specified in the Supply and Quality Documentation, including such documentation as is necessary to allow the Recipient to compare the BMS Study Drug certificate of analysis to the BMS Study Drug specifications. Pursuant to the Supply and Quality Documentation, BMS shall be responsible for the regulatory compliance of the quality of the BMS Study Drug at the time the BMS Study Drug is delivered to the Recipient with the regulatory filings in the countries in the Territory where the Combined Therapy Clinical Trial will be performed. Subject to Section 4.4, the Parties shall cooperate in accordance with Applicable Law to minimize indirect taxes (such as value added tax, sales tax, consumption tax and other similar taxes) relating to the BMS Study Drug in connection with this Agreement.

  • Supply of Products TheraSense shall be responsible for the ------------------ manufacture of FreeStyle Products for sale to Nipro.

  • Manufacturing Agreement Each of the Sellers (as applicable) shall have executed and delivered to the Buyer the Manufacturing Agreement with respect to the portion of the Business conducted at the applicable Facility.

  • Manufacture of Products All Products marketed through Grantor's Web ------------------------- Site shall be manufactured, packaged, prepared, and shipped in accordance with the specifications and requirements described on Exhibit A hereto as it may be modified from time to time. Quality control standards relating to the Product's weight, color, consistency, micro-biological content, labeling and packaging are also set forth on Exhibit A. In the event that Exhibit A is incomplete, Products shall be manufactured and shipped in accordance with industry standards.

Time is Money Join Law Insider Premium to draft better contracts faster.